Kezar Life Sciences, Inc. (NASDAQ:KZR – Get Rating) – Research analysts at William Blair issued their Q1 2024 earnings estimates for shares of Kezar Life Sciences in a report released on Wednesday, March 15th. William Blair analyst M. Phipps forecasts that the company will post earnings per share of ($0.26) for the quarter. William Blair currently has a “Market Perform” rating on the stock. The consensus estimate for Kezar Life Sciences’ current full-year earnings is ($1.25) per share. William Blair also issued estimates for Kezar Life Sciences’ Q2 2024 earnings at ($0.25) EPS, Q3 2024 earnings at ($0.22) EPS and Q4 2024 earnings at ($0.20) EPS.
KZR has been the subject of a number of other reports. Wells Fargo & Company lowered their price target on shares of Kezar Life Sciences from $17.00 to $14.00 and set an “overweight” rating for the company in a report on Tuesday, January 3rd. HC Wainwright reaffirmed a “buy” rating and set a $21.00 price target on shares of Kezar Life Sciences in a report on Thursday.
Kezar Life Sciences Price Performance
Insiders Place Their Bets
In other Kezar Life Sciences news, major shareholder Morningside Venture Investment sold 5,000 shares of the firm’s stock in a transaction on Thursday, January 12th. The shares were sold at an average price of $6.77, for a total transaction of $33,850.00. Following the completion of the transaction, the insider now directly owns 5,881,078 shares of the company’s stock, valued at approximately $39,814,898.06. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders sold a total of 248,276 shares of company stock valued at $1,708,683 in the last ninety days. Corporate insiders own 7.80% of the company’s stock.
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the stock. Great West Life Assurance Co. Can acquired a new position in Kezar Life Sciences during the 3rd quarter worth $26,000. Amundi acquired a new position in shares of Kezar Life Sciences in the 4th quarter valued at about $32,000. Tower Research Capital LLC TRC boosted its holdings in shares of Kezar Life Sciences by 88.9% in the 3rd quarter. Tower Research Capital LLC TRC now owns 6,777 shares of the company’s stock valued at $58,000 after buying an additional 3,190 shares during the period. Robeco Institutional Asset Management B.V. acquired a new position in shares of Kezar Life Sciences in the 3rd quarter valued at about $68,000. Finally, UBS Asset Management Americas Inc. acquired a new position in shares of Kezar Life Sciences in the 3rd quarter valued at about $86,000. 84.03% of the stock is owned by institutional investors and hedge funds.
Kezar Life Sciences Company Profile
Kezar Life Sciences, Inc is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer in South San Francisco and California. Its product pipeline include KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J.
- Get a free copy of the StockNews.com research report on Kezar Life Sciences (KZR)
- Don’t Miss Out: $2 Trillion Could be Headed to the Banking Sector
- A Weakening Economy Suggests Caution Before Buying Five Below
- Williams-Sonoma: Time To Buy At Rock-Bottom Prices
- Why DraftKings Could Keep Outperforming in 2023
- Charles Schwab And The Safest 30% You Can Make This Year
Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.